First-in-human phase I/II dose-escalation and randomized dose-optimization study of SOT109 in advanced colorectal cancer
Sponsor: SOTIO Biotech a.s.
Phase: 1, 2
Disease: Unresectable or metastatic colorectal adenocarcinoma
EU trial number: 2026-526235-19-00
Population: Adults with advanced unresectable or metastatic colorectal cancer who have exhausted or have no further satisfactory standard systemic treatment options, enrolled into early dose escalation or two-dose randomized optimization of SOT109 antibody-drug conjugate monotherapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?